CN109803674A - Calr和jak2疫苗组合物 - Google Patents

Calr和jak2疫苗组合物 Download PDF

Info

Publication number
CN109803674A
CN109803674A CN201780048646.9A CN201780048646A CN109803674A CN 109803674 A CN109803674 A CN 109803674A CN 201780048646 A CN201780048646 A CN 201780048646A CN 109803674 A CN109803674 A CN 109803674A
Authority
CN
China
Prior art keywords
seq
amino acid
calr
peptide
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780048646.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·安德森
M·O·霍姆斯特罗姆
H·哈塞尔巴赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of CN109803674A publication Critical patent/CN109803674A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780048646.9A 2016-06-10 2017-06-09 Calr和jak2疫苗组合物 Pending CN109803674A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670417 2016-06-10
DKPA201670417 2016-06-10
PCT/DK2017/050190 WO2017211371A2 (en) 2016-06-10 2017-06-09 Calr and jak2 vaccine compositions

Publications (1)

Publication Number Publication Date
CN109803674A true CN109803674A (zh) 2019-05-24

Family

ID=59284957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780048646.9A Pending CN109803674A (zh) 2016-06-10 2017-06-09 Calr和jak2疫苗组合物

Country Status (8)

Country Link
US (1) US20190328857A1 (enExample)
EP (1) EP3468585A2 (enExample)
JP (1) JP2019517544A (enExample)
CN (1) CN109803674A (enExample)
AU (1) AU2017276498A1 (enExample)
CA (1) CA3026572A1 (enExample)
IL (1) IL263574A (enExample)
WO (1) WO2017211371A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111087448A (zh) * 2019-12-23 2020-05-01 维塔恩(广州)医药有限公司 肿瘤相关基因jak2突变相关抗原短肽及其应用
CN112168829A (zh) * 2020-09-24 2021-01-05 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物
CN114980920A (zh) * 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
EP4121081A4 (en) * 2020-03-17 2024-04-17 Memorial Sloan Kettering Cancer Center VACCINES AGAINST HETEROCLITIC CANCER
CN115380079B (zh) 2020-04-15 2025-04-25 3M创新有限公司 可堆肥组合物、可堆肥制品以及制备可堆肥制品的方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022216574A1 (en) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
CA3242956A1 (en) * 2021-12-16 2023-06-22 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
US20250352627A1 (en) * 2022-06-17 2025-11-20 Ichan School Of Medicine At Mount Sinai Mutant calr-peptide based vaccine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223038A1 (en) * 1995-06-05 1996-12-12 Jeffrey J. Seilhamer A c5a-like seven transmembrane receptor
EP2808338A1 (en) * 2013-09-16 2014-12-03 CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
US20150010575A1 (en) * 2013-07-03 2015-01-08 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-c-met antibody
CN104561287A (zh) * 2014-12-26 2015-04-29 南京艾迪康医学检验所有限公司 检测calr基因第9外显子突变的试剂和方法
CN105441562A (zh) * 2015-12-31 2016-03-30 德赛诊断系统(上海)有限公司 Carl基因缺失、插入突变的检测方法及试剂盒
WO2016087514A1 (en) * 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
WO2007047653A2 (en) * 2005-10-17 2007-04-26 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
HUE037973T2 (hu) 2008-04-17 2018-09-28 Io Biotech Aps Indolamin-2,3-dioxigenáz-alapú immunterápia
BR112014009526B8 (pt) 2011-10-17 2023-01-17 Herlev Hospital Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223038A1 (en) * 1995-06-05 1996-12-12 Jeffrey J. Seilhamer A c5a-like seven transmembrane receptor
US20150010575A1 (en) * 2013-07-03 2015-01-08 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-c-met antibody
EP2808338A1 (en) * 2013-09-16 2014-12-03 CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
WO2016087514A1 (en) * 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CN104561287A (zh) * 2014-12-26 2015-04-29 南京艾迪康医学检验所有限公司 检测calr基因第9外显子突变的试剂和方法
CN105441562A (zh) * 2015-12-31 2016-03-30 德赛诊断系统(上海)有限公司 Carl基因缺失、插入突变的检测方法及试剂盒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUNG-SOOK HA等: "Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms", 《ANN LAB MED》 *
常春康: "骨髓增殖性肿瘤中的钙网蛋白基因突变", 《诊断学理论与实践》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114980920A (zh) * 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
CN111087448A (zh) * 2019-12-23 2020-05-01 维塔恩(广州)医药有限公司 肿瘤相关基因jak2突变相关抗原短肽及其应用
CN112168829A (zh) * 2020-09-24 2021-01-05 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Also Published As

Publication number Publication date
EP3468585A2 (en) 2019-04-17
CA3026572A1 (en) 2017-12-14
AU2017276498A1 (en) 2019-01-03
US20190328857A1 (en) 2019-10-31
WO2017211371A3 (en) 2018-01-18
JP2019517544A (ja) 2019-06-24
IL263574A (en) 2019-01-31
WO2017211371A2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
CN109803674A (zh) Calr和jak2疫苗组合物
CN109152830B (zh) 用于免疫疗法的核/壳结构平台
US11529403B2 (en) Telomerase polypeptide vaccine for treating cancer
ES2657963T3 (es) Inmunoterapia basada en indolamina 2,3-dioxigenasa
CN109310739A (zh) 新抗原及其使用方法
CN112638404A (zh) 新抗原及其用途
CN109890408A (zh) 新表位疫苗组合物及其使用方法
KR20170121178A (ko) 보편적인 살해 t-세포
JP2022500022A (ja) Ｔ細胞改変
KR20150002706A (ko) 종양 형성 치료방법
JP2022551918A (ja) マルチドメインタンパク質ワクチン
CA3211565A1 (en) Uses of amphiphiles in immune cell therapy and compositions therefor
Jeon et al. Cell-based IL-15: IL-15Rα secreting vaccine as an effective therapy for CT26 colon cancer in mice
Yang et al. Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses
JP6811710B2 (ja) トリプトファン２，３−ジオキシゲナーゼまたはそのフラグメントを含むワクチン組成物
DE60114780T2 (de) Hyperthermie und immunotherapie für leukaemien, lymphomas und feste tumore
JPWO2017026389A1 (ja) 免疫誘導剤
Weigel et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses
CN109891238A (zh) 免疫治疗剂的剂量确定
US12144851B2 (en) Vaccinal strategy
US20230346901A1 (en) Methods and vaccine compositions to treat cancers
RU2773273C2 (ru) Неоантигены и способы их использования
Guinipero et al. Cancer vaccines: Emphasis on pediatric cancers
Sistigu Inflammatory and immune reactions in response to chemotherapy-induced cell death
HK40050845A (en) Neoantigens and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190524